C2i Genomics, an Israeli medtech startup that develops new procedures for the treatment of cancer, is being acquired by American cancer diagnostics company Veracyte for as much as $95 million. Veracyte will pay $70 million in Veracyte shares at closing, and up to an additional $25 million based on the achievement of future performance milestones […]
JPM24: Veracyte inks $95M deal to buy fellow cancer testing company C2i Genomics fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Grew full-year revenue to between $358 million and $359 million, an increase of 21%
Acquisition broadens Veracyte’s presence across the cancer care continuum
.
Glaukos (NYSE:GKOS – Free Report) had its price objective increased by Piper Sandler from $90.00 to $105.00 in a research note issued to investors on Friday morning, Benzinga reports. The firm currently has an overweight rating on the medical instruments supplier’s stock. Other equities research analysts also recently issued research reports about the stock. Stifel […]